Literature DB >> 18648323

Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys.

Alison L McCormack1, Sally K Mak, Maryam Shenasa, William J Langston, Lysia S Forno, Donato A Di Monte.   

Abstract

alpha-Synuclein expression is increased in dopaminergic neurons challenged by toxic insults. Here, we assessed whether this upregulation is accompanied by pathologic accumulation of alpha-synuclein and protein modifications (i.e. nitration, phosphorylation, and aggregation) that are typically observed in Parkinson disease and in other synucleinopathies. A single injection of the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to squirrel monkeys caused a buildup of alpha-synuclein but not of beta-synuclein or synaptophysin within nigral dopaminergic cell bodies. Immunohistochemistry and immunoelectron microscopy also revealed large numbers of dystrophic axons labeled with alpha-synuclein. Antibodies that recognize nitrated and phosphorylated (at serine 129) alpha-synuclein stained neuronal cell bodies and dystrophic axons in the midbrain of MPTP-treated animals. After toxicant exposure, alpha-synuclein deposition occurred at the level of neuronal axons in which amorphous protein aggregates were observed by immunoelectron microscopy. In a subset of these axons, immunoreactivity for alpha-synuclein was still evident after tissue digestion with proteinase K, further indicating the accumulation of insoluble protein. These data indicate that toxic injury can induce alpha-synuclein modifications that have been implicated in the pathogenesis of human synucleinopathies. The findings are also consistent with a pattern of evolution of alpha-synuclein pathology that may begin with the accumulation and aggregation of the protein within damaged axons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18648323      PMCID: PMC2745435          DOI: 10.1097/NEN.0b013e318180f0bd

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  52 in total

1.  Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.

Authors:  Francesco Fornai; Paola Lenzi; Michela Ferrucci; Gloria Lazzeri; Adolfo Bandettini di Poggio; Gianfranco Natale; Carla L Busceti; Francesca Biagioni; Mario Giusiani; Stefano Ruggieri; Antonio Paparelli
Journal:  Brain Res Bull       Date:  2005-05-15       Impact factor: 4.077

2.  Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.

Authors:  Wei Zhang; Tongguang Wang; Zhong Pei; David S Miller; Xuefei Wu; Michelle L Block; Belinda Wilson; Wanqin Zhang; Yong Zhou; Jau-Shyong Hong; Jing Zhang
Journal:  FASEB J       Date:  2005-04       Impact factor: 5.191

3.  Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

Authors:  Mika Shimoji; Li Zhang; Allen S Mandir; Valina L Dawson; Ted M Dawson
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

4.  Effects of nitration on the structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; Ghiam Yamin; Larissa A Munishkina; Mikhail A Karymov; Ian S Millett; Sebastian Doniach; Yuri L Lyubchenko; Anthony L Fink
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

5.  Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients.

Authors:  Daniela Berg; Marc Niwar; Sylvia Maass; Alexander Zimprich; J Carsten Möller; Ullrich Wuellner; Tanja Schmitz-Hübsch; Christine Klein; Eng-King Tan; Ludger Schöls; Laura Marsh; Ted M Dawson; Bernd Janetzky; Thomas Müller; Dirk Woitalla; Vladimir Kostic; Peter P Pramstaller; Wolfgang H Oertel; Peter Bauer; Rejko Krueger; Thomas Gasser; Olaf Riess
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

6.  Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage.

Authors:  Manuela Neumann; Veronika Müller; Hans A Kretzschmar; Christian Haass; Philipp J Kahle
Journal:  J Neuropathol Exp Neurol       Date:  2004-12       Impact factor: 3.685

7.  Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.

Authors:  Heiko Braak; Magdalena Sastre; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2007-06-19       Impact factor: 17.088

8.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.

Authors:  P H Tu; J E Galvin; M Baba; B Giasson; T Tomita; S Leight; S Nakajo; T Iwatsubo; J Q Trojanowski; V M Lee
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation.

Authors:  Roberto Hodara; Erin H Norris; Benoit I Giasson; Amanda J Mishizen-Eberz; David R Lynch; Virginia M-Y Lee; Harry Ischiropoulos
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

10.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.

Authors:  Wanli W Smith; Russell L Margolis; Xiaojie Li; Juan C Troncoso; Michael K Lee; Valina L Dawson; Ted M Dawson; Takashi Iwatsubo; Christopher A Ross
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.709

View more
  31 in total

1.  Environmental neurotoxin-induced progressive model of parkinsonism in rats.

Authors:  Wei-Bin Shen; Kimberly A McDowell; Aubrey A Siebert; Sarah M Clark; Natalie V Dugger; Kimberly M Valentino; H A Jinnah; Carole Sztalryd; Paul S Fishman; Christopher A Shaw; M Samir Jafri; Paul J Yarowsky
Journal:  Ann Neurol       Date:  2010-07       Impact factor: 10.422

2.  Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding.

Authors:  Eva Sevcsik; Adam J Trexler; Joanna M Dunn; Elizabeth Rhoades
Journal:  J Am Chem Soc       Date:  2011-04-14       Impact factor: 15.419

Review 3.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

4.  Lysosomal degradation of alpha-synuclein in vivo.

Authors:  Sally K Mak; Alison L McCormack; Amy B Manning-Bog; Ana Maria Cuervo; Donato A Di Monte
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

Review 5.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 6.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

7.  Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Authors:  Haiyan Lou; Susana E Montoya; Tshianda N M Alerte; Jian Wang; Jianjun Wu; Xiangmin Peng; Chang-Sook Hong; Emily E Friedrich; Samantha A Mader; Courtney J Pedersen; Brian S Marcus; Alison L McCormack; Donato A Di Monte; S Colette Daubner; Ruth G Perez
Journal:  J Biol Chem       Date:  2010-03-31       Impact factor: 5.157

8.  Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra.

Authors:  Alison L McCormack; Sally K Mak; Jaimie M Henderson; David Bumcrot; Matthew J Farrer; Donato A Di Monte
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

Review 9.  Beyond muscles: The untapped potential of creatine.

Authors:  Lisa A Riesberg; Stephanie A Weed; Thomas L McDonald; Joan M Eckerson; Kristen M Drescher
Journal:  Int Immunopharmacol       Date:  2016-01-08       Impact factor: 4.932

10.  Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Authors:  Xiao-Hong Lu; Sheila M Fleming; Bernhard Meurers; Larry C Ackerson; Farzad Mortazavi; Victor Lo; Daniela Hernandez; David Sulzer; George R Jackson; Nigel T Maidment; Marie-Francoise Chesselet; X William Yang
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.